Our top pick for
Atrion Corporation is a medical instruments & supplies business based in the US. Atrion Corporation shares (ATRI) are listed on the NASDAQ and all prices are listed in US Dollars. Atrion Corporation employs 636 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$563.88 - $743.09|
|50-day moving average||$653.85|
|200-day moving average||$644.03|
|Wall St. target price||$300.00|
|Dividend yield||$6.6 (1.02%)|
|Earnings per share (TTM)||$17.44|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Atrion Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atrion Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atrion Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Atrion Corporation shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Atrion Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $47.3 million.
The EBITDA is a measure of a Atrion Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$147.6 million|
|Operating margin TTM||24.17%|
|Gross profit TTM||$66.2 million|
|Return on assets TTM||8.43%|
|Return on equity TTM||13.43%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 65,187 Atrion Corporation shares held short by investors – that's known as Atrion Corporation's "short interest". This figure is 0.6% down from 65,553 last month.
There are a few different ways that this level of interest in shorting Atrion Corporation shares can be evaluated.
Atrion Corporation's "short interest ratio" (SIR) is the quantity of Atrion Corporation shares currently shorted divided by the average quantity of Atrion Corporation shares traded daily (recently around 6518.7). Atrion Corporation's SIR currently stands at 10. In other words for every 100,000 Atrion Corporation shares traded daily on the market, roughly 10000 shares are currently held short.
However Atrion Corporation's short interest can also be evaluated against the total number of Atrion Corporation shares, or, against the total number of tradable Atrion Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atrion Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Atrion Corporation shares in existence, roughly 40 shares are currently held short) or 0.0616% of the tradable shares (for every 100,000 tradable Atrion Corporation shares, roughly 62 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atrion Corporation.
Find out more about how you can short Atrion Corporation stock.
Dividend payout ratio: 40.79% of net profits
Recently Atrion Corporation has paid out, on average, around 40.79% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.08% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Atrion Corporation shareholders could enjoy a 1.08% return on their shares, in the form of dividend payments. In Atrion Corporation's case, that would currently equate to about $6.6 per share.
While Atrion Corporation's payout ratio might seem fairly standard, it's worth remembering that Atrion Corporation may be investing much of the rest of its net profits in future growth.
Atrion Corporation's most recent dividend payout was on 30 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 11 March 2021 (the "ex-dividend date").
Atrion Corporation's shares were split on a 3:2 basis on 2 December 1996. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Atrion Corporation shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Atrion Corporation shares which in turn could have impacted Atrion Corporation's share price.
Over the last 12 months, Atrion Corporation's shares have ranged in value from as little as $563.878 up to $743.0855. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atrion Corporation's is 0.0954. This would suggest that Atrion Corporation's shares are less volatile than average (for this exchange).
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.